Biogen | BIIB - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
AbbVie USD 5.57B 2.9B 2026-03
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
ALKERMES USD 100.74M 4.1M 2025-09
Amgen USD 1.51B 2.41B 2025-12
Bayer EUR -1.16B 735M 2025-09
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Esperion Therapeutics USD 63.67M 95M 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
Incyte USD 389.94M 92.37M 2025-12
Merck USD 3.42B 3.32B 2025-12
Moderna USD -187M 631M 2025-09
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 4.64B 445M 2025-12
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR -1.16B 5.5B 2025-12
Sanofi EUR -1.16B 6.23B 2025-12
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Teva Pharmaceutical Industries USD 753M 662M 2026-03
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
United Therapeutics USD 444M 6M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09